DCCancerDoc's profile picture. Cancer Doctor in Washington, D.C. Sherlock loving Hematologist Oncologist. Data science and informatics lover. Reality 🧜‍♀️ 🎹 🎤⚽️

Dalia M.

@DCCancerDoc

Cancer Doctor in Washington, D.C. Sherlock loving Hematologist Oncologist. Data science and informatics lover. Reality 🧜‍♀️ 🎹 🎤⚽️

Exciting presentation at #ET24 Thank you @NaglaAKarimMD and the speakers

@DCCancerDoc⁩ chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! ⁦@InovaCME⁩ ⁦@InovaSchar⁩ ⁦@InovaHealth

NaglaAKarimMD's tweet image. ⁦@DCCancerDoc⁩ chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! ⁦@InovaCME⁩ ⁦@InovaSchar⁩ ⁦@InovaHealth⁩


Dalia M. reposted

@DCCancerDoc⁩ chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! ⁦@InovaCME⁩ ⁦@InovaSchar⁩ ⁦@InovaHealth

NaglaAKarimMD's tweet image. ⁦@DCCancerDoc⁩ chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! ⁦@InovaCME⁩ ⁦@InovaSchar⁩ ⁦@InovaHealth⁩

Dalia M. reposted

@MPishvaian⁩ How to improve accrual/Discover the clues to success of Phase I Programs #ET24@InovaSchar⁩ ⁦@InovaHealth⁩ ⁦@InovaCME

NaglaAKarimMD's tweet image. ⁦@MPishvaian⁩ How to improve accrual/Discover the clues to success of Phase I Programs #ET24 ⁦@InovaSchar⁩ ⁦@InovaHealth⁩ ⁦@InovaCME⁩

Dalia M. reposted

@AnwaarSaeed3⁩ presents Novel Agents Exploration in MRD Positive Colorectal Cancer Post Definitive Surgery and Chemotherapy. Excellent point of utilizing potentially effective novel agents in the adjuvant setting #ET24

NaglaAKarimMD's tweet image. ⁦@AnwaarSaeed3⁩ presents Novel Agents Exploration in MRD Positive Colorectal Cancer Post Definitive Surgery and Chemotherapy. Excellent point of utilizing potentially effective novel agents in the adjuvant setting #ET24
NaglaAKarimMD's tweet image. ⁦@AnwaarSaeed3⁩ presents Novel Agents Exploration in MRD Positive Colorectal Cancer Post Definitive Surgery and Chemotherapy. Excellent point of utilizing potentially effective novel agents in the adjuvant setting #ET24

Finally met papa Hem in person Symposium for Evolving Therapies and Drug Development in Oncology INOVA @AaronGoodman33 @NaglaAKarimMD

DCCancerDoc's tweet image. Finally met papa Hem in person
 
Symposium for Evolving Therapies and Drug Development in Oncology
INOVA

@AaronGoodman33 
@NaglaAKarimMD

Excellent talk on AML at 2024 Hematology Update Symposium by Dr. Nassereddine

DCCancerDoc's tweet image. Excellent talk on AML at 2024 Hematology Update Symposium by 
Dr. Nassereddine

Dalia M. reposted

Do your best work to prolong life and alleviate suffering, advocate tirelessly for your patients, have a life outside of medicine - and always remember that it is the patient's story that you were privileged to witness and play a role in, not your story.


🇲🇦🇲🇦🇲🇦

MOROCCO TOPS GROUP F! 🇲🇦 THE FIRST AFRICAN TEAM TO WIN THEIR GROUP THIS CENTURY 👏

ESPNFC's tweet image. MOROCCO TOPS GROUP F! 🇲🇦 

THE FIRST AFRICAN TEAM TO WIN THEIR GROUP THIS CENTURY 👏


Dalia M. reposted

#سورة_الكهف #يوم_الجمعة اسقوا غِراس جُمعتكم بـ سورة الكهف فإنها نورٌ بين الجُمعتين .. 🤍

salimsadaqa's tweet image. #سورة_الكهف
 #يوم_الجمعة 
اسقوا غِراس جُمعتكم بـ سورة الكهف
فإنها نورٌ بين الجُمعتين .. 🤍
salimsadaqa's tweet image. #سورة_الكهف
 #يوم_الجمعة 
اسقوا غِراس جُمعتكم بـ سورة الكهف
فإنها نورٌ بين الجُمعتين .. 🤍
salimsadaqa's tweet image. #سورة_الكهف
 #يوم_الجمعة 
اسقوا غِراس جُمعتكم بـ سورة الكهف
فإنها نورٌ بين الجُمعتين .. 🤍
salimsadaqa's tweet image. #سورة_الكهف
 #يوم_الجمعة 
اسقوا غِراس جُمعتكم بـ سورة الكهف
فإنها نورٌ بين الجُمعتين .. 🤍

This

Over time I’ve tweeted a lot about evidence-based medicine. But oncologists are often in situations with little or no evidence to guide them. In these situations we go to “first principles”. But what are the first principles? Here’s a thread outlining those I think are key.



Small Cell Lung Cancer SCLC SOC discussed by Dr. @StephenVLiu at #DCLung22 with highlights including promising agents. Scratching the surface still with biomarkers

DCCancerDoc's tweet image. Small Cell Lung Cancer SCLC SOC discussed by Dr. @StephenVLiu at #DCLung22 with highlights including promising agents. Scratching the surface still with biomarkers
DCCancerDoc's tweet image. Small Cell Lung Cancer SCLC SOC discussed by Dr. @StephenVLiu at #DCLung22 with highlights including promising agents. Scratching the surface still with biomarkers
DCCancerDoc's tweet image. Small Cell Lung Cancer SCLC SOC discussed by Dr. @StephenVLiu at #DCLung22 with highlights including promising agents. Scratching the surface still with biomarkers
DCCancerDoc's tweet image. Small Cell Lung Cancer SCLC SOC discussed by Dr. @StephenVLiu at #DCLung22 with highlights including promising agents. Scratching the surface still with biomarkers

Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM

StephenVLiu's tweet image. Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM
StephenVLiu's tweet image. Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM
StephenVLiu's tweet image. Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM
StephenVLiu's tweet image. Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM


Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago!

StephenVLiu's tweet image. Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago!
StephenVLiu's tweet image. Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago!
StephenVLiu's tweet image. Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago!
StephenVLiu's tweet image. Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago!


Screening saves lives #DCLung22

Dr. @BrendonStilesMD explains why all of us need to be involved with lung cancer screening, addressing some of the common misconceptions and stressing that screening saves lives. #DCLung22 #LCSM

StephenVLiu's tweet image. Dr. @BrendonStilesMD explains why all of us need to be involved with lung cancer screening, addressing some of the common misconceptions and stressing that screening saves lives. #DCLung22 #LCSM
StephenVLiu's tweet image. Dr. @BrendonStilesMD explains why all of us need to be involved with lung cancer screening, addressing some of the common misconceptions and stressing that screening saves lives. #DCLung22 #LCSM
StephenVLiu's tweet image. Dr. @BrendonStilesMD explains why all of us need to be involved with lung cancer screening, addressing some of the common misconceptions and stressing that screening saves lives. #DCLung22 #LCSM
StephenVLiu's tweet image. Dr. @BrendonStilesMD explains why all of us need to be involved with lung cancer screening, addressing some of the common misconceptions and stressing that screening saves lives. #DCLung22 #LCSM


Dalia M. reposted

Learning about the potential benefit of proton beam radiation from Dr. @NitikaPaudel at #DCLung22 - single gantry model at @LombardiCancer shown. Newer technology showing less exposure vs passive scatter. Awaiting results from ongoing #RTOG study.

StephenVLiu's tweet image. Learning about the potential benefit of proton beam radiation from Dr. @NitikaPaudel at #DCLung22 - single gantry model at @LombardiCancer shown. Newer technology showing less exposure vs passive scatter. Awaiting results from ongoing #RTOG study.
StephenVLiu's tweet image. Learning about the potential benefit of proton beam radiation from Dr. @NitikaPaudel at #DCLung22 - single gantry model at @LombardiCancer shown. Newer technology showing less exposure vs passive scatter. Awaiting results from ongoing #RTOG study.
StephenVLiu's tweet image. Learning about the potential benefit of proton beam radiation from Dr. @NitikaPaudel at #DCLung22 - single gantry model at @LombardiCancer shown. Newer technology showing less exposure vs passive scatter. Awaiting results from ongoing #RTOG study.
StephenVLiu's tweet image. Learning about the potential benefit of proton beam radiation from Dr. @NitikaPaudel at #DCLung22 - single gantry model at @LombardiCancer shown. Newer technology showing less exposure vs passive scatter. Awaiting results from ongoing #RTOG study.

This #HEDS

.@DocZing treats patients with connective tissue disorders and Ehlers-Danlos Syndrome. Dr. Zingman was featured in Physician Outlook Magazine in 2020 and we revisit her today as she makes strides to reshape the face of medicine as we know it. physicianoutlook.com/articles/inter…



Dalia M. reposted

Vedic mathematics has made India smarter in world of competition. #education #Mathematics


Perfect description y’all

A non-medical friend recently asked me to describe clinic. I told her to imagine you have 20 meetings in a day, half of them new clients with urgent needs. Each requires your best self. You are late for at least 10 of them. You must prepare a report and deliverables for each one.



Dalia M. reposted

Is the paper you need stuck behind a paywall? Five websites every researcher should know to access any research paper for free @AcademicChatter @OpenAcademics


Loading...

Something went wrong.


Something went wrong.